ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

CINGW Cingulate Inc

0,02
0,00 (0,00%)
Nach Börsenschluss
Zuletzt aktualisiert: 22:00:02
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Cingulate Inc CINGW NASDAQ Equity Warrant
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 0,02 22:00:02
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,0199 0,0199 0,02 0,02 0,02
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
28.5.202423:54EDGAR2Form SC 13D/A - General statement of acquisition of..
28.5.202415:20EDGAR2Form 8-K - Current report
24.5.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
23.5.202423:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21.5.202415:00GLOBEFDA Clears Cingulate to File for Marketing Approval of..
17.5.202423:01EDGAR2Form S-1 - General form for registration of securities under..
13.5.202414:00EDGAR2Form 8-K - Current report
08.5.202413:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.5.202413:10EDGAR2Form 8-K - Current report
08.5.202413:00GLOBECingulate Reports First Quarter 2024 Financial Results and..
30.4.202411:45GLOBEPeter J. Werth, Successful Pharma Entrepreneur,..
16.4.202423:00GLOBECingulate to Participate in Planet MicroCap Showcase: Vegas..
01.4.202414:00GLOBECingulate Inc. Reports Fourth Quarter and Full Year 2023..
19.3.202421:45GLOBECingulate to Participate in Benzinga All Live Access Event
06.3.202412:45GLOBECingulate to Attend DCAT Week 2024 in New York City
13.2.202412:45GLOBECingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff..
06.2.202422:15GLOBECingulate Announces Closing of $7.5 Million Public Offering
02.2.202415:15GLOBECingulate Announces Pricing of $7.5 Million Public Offering
29.1.202414:00GLOBELongtime Cingulate Controller Jennifer Callahan Promoted to..
29.1.202412:45GLOBEWerth Family Investment Associates Converts Remaining $3.3M..
01.12.202315:00GLOBECingulate Receives Guidance from FDA on Path Forward for..
13.11.202322:15GLOBECingulate Inc. Reports Third Quarter 2023 Financial..
17.10.202320:22GLOBECingulate to Host CNS Key Opinion Leader Panel in New York..
21.9.202319:30GLOBECingulate Inc. to Present at the LD Micro Main Event XVI
13.9.202322:15GLOBECingulate Announces Closing of $4.0 Million Public Offering
11.9.202315:22GLOBECingulate Announces Pricing of $4.0 Million Public Offering
11.9.202312:00GLOBECingulate Announces Detailed Trial Results from Phase 3..
08.9.202322:31GLOBEWerth Family Investment Associates Converts $5.8 Million of..
05.9.202314:00GLOBECingulate Announces Presentation of Full Trial Results from..
14.8.202322:15GLOBECingulate Inc. Reports Second Quarter 2023 Financial..
11.7.202314:00GLOBECingulate Announces Positive Top-Line Results from Phase 3..
29.6.202314:00GLOBECingulate Successfully Manufactures Clinical Supply –..
14.6.202321:45GLOBECingulate to Participate in the Healthcare Virtual..
08.6.202313:00GLOBECingulate Completes Phase 3 Adult Trial of CTx-1301..